(Q77128791)

English

Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor

scientific article published on 01 March 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

Michael Krainer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

author name string

H Stöger

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

H Samonigg

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M Ploszczynski

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

G Nirnberger

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

S Maca

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

W Hehenwarter

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M Wirth

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

J Schüller

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

N Vavra

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

W Scheithauer

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

G Kornek

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

M Stierer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

C C Zielinski

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

publication date

1 March 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

482-488

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification and breast cancer: current results and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910039-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(97)10039-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9713297%20AND%20SRC:MED&resulttype=core&format=json

3 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q77128791&oldid=1756359406"